Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis
- 2 March 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (19), 1672-1686f
- https://doi.org/10.1093/eurheartj/ehy066
Abstract
The success of trials that have shown net clinical benefits of antithrombotic drugs as well as the increasing prevalence of cardiovascular diseases in an ageing population have led to more widespread use of antiplatelet and anticoagulant drugs. At the same time, extremely low and high body weight (BW) are becoming more common due to a higher prevalence of frailty, associated with greater life expectancy, and the global epidemic of obesity, ‘globesity’, respectively.1–3 These extreme BWs may affect cardiovascular risk as well as the pharmacokinetics of antithrombotic drugs, some of which have relatively narrow therapeutic windows.This publication has 209 references indexed in Scilit:
- Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients: Results From the FEATHER TrialJournal of the American College of Cardiology, 2012
- Association of obesity with cerebral microbleeds in neurologically asymptomatic elderly subjectsZeitschrift für Neurologie, 2012
- Tissue factor and cell signalling in cancer progression and thrombosisJournal of Thrombosis and Haemostasis, 2011
- Association between general and central adiposity in childhood, and change in these, with cardiovascular risk factors in adolescence: prospective cohort studyBMJ, 2010
- Body mass index and bleeding complications after percutaneous coronary intervention: Does bivalirudin make a difference?American Heart Journal, 2010
- Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patientsThrombosis Research, 2010
- Macrophages, Inflammation, and Insulin ResistanceAnnual Review of Physiology, 2010
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studiesThe Lancet, 2009